Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published Date April 2008 Volume 2008:4(2) Pages 337—344

DOI http://dx.doi.org/10.2147/TCRM.S1209

Published 21 April 2008

Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery

Vasconcelos A, Vega E, Pérez Y, Gómara MJ, García ML, Haro I

International Journal of Nanomedicine 2015, 10:609-631

Published Date: 27 January 2015

Ag-plasma modification enhances bone apposition around titanium dental implants: an animal study in Labrador dogs

Qiao SC, Cao HL, Zhao X, Lo HW, Zhuang LF, Gu YX, Shi JY, Liu XY, Lai HC

International Journal of Nanomedicine 2015, 10:653-664

Published Date: 14 January 2015

Toxicology of antimicrobial nanoparticlesfor prosthetic devices

Nuñez-Anita RE, Acosta-Torres LS, Vilar-Pineda J, Martínez-Espinosa JC, de la Fuente-Hernández J, Castaño VM

International Journal of Nanomedicine 2014, 9:3999-4006

Published Date: 20 August 2014

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib

Rajendra R, Jones RL, Pollack SM

OncoTargets and Therapy 2013, 6:217-222

Published Date: 18 March 2013

A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations

Karavana SY, Gökçe EH, Rençber S, Özbal S, Pekçetin Ç, Güneri P, Ertan G

International Journal of Nanomedicine 2012, 7:5693-5704

Published Date: 9 November 2012

Writing 3D patterns of microvessels

Juodkazis S

International Journal of Nanomedicine 2012, 7:3701-3702

Published Date: 13 July 2012

Corrigendum

Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method

Jafarzadeh Kashi TS, Eskandarion S, Esfandyari-Manesh M, Amin Marashi SM, Samadi N, Fatemi SM, Atyabi F, Eshraghi S, Dinarvand R

International Journal of Nanomedicine 2012, 7:221-234

Published Date: 10 January 2012

Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy

Yan Feng, Marc R Gastonguay, Bruce G Pollock, et al

Neuropsychiatric Disease and Treatment 2011, 7:117-125

Published Date: 17 March 2011